

Management of Acute Severe Asthma

Dr. Binod Kumar Singh

Medical Superintendent, NMCH, Patna

Professor & Head

Dept. of Pediatrics, NMCH, Patna

IAP State President, Bihar- 2019

IAP State Vice-President, Bihar- 2018

CIAP Executive board member-2015

NNF State president, Bihar- 2014

IAP State secretary, Bihar-2010-2011

NNF State secretary, Bihar-2008-2009


Fellow of Indian Academy of Pediatrics (FIAP)




Chief Consultant
Shiv Shishu Hospital

K-208, P.C Colony, Hanuman Nagar,
Patna - 800020

Web site : www.shivshishuhospital.org, Mob:-9431047667

- ❖ Chronic inflammatory disorder of the airway
 - ❖ Characterized by recurrent episodes of wheezing, breathlessness and coughing
 - ❖ Global prevalence: 1-18% of the population in different countries
 - ❖ Annual world wide death from asthma: 250,000
 - ❖ No data regarding incidence of acute asthma exacerbation in children in India
- 

- ❖ **Exacerbation of asthma** are episodes characterised by a progressive increase in symptoms of shortness of breath, cough, wheezing and chest tightness.
 - ❖ **Acute severe asthma**, formerly known as status asthmaticus, is defined as severe asthma **unresponsive to** repeated course of nebulised bronchodilator agents(beta- agonist therapy).
- 

Pathophysiology


❖ Primary pathophysiology:

- Airway inflammation & hyper-reactivity
- Smooth muscle spasm
- Mucosal edema & plugging

❖ Pathologic changes in airway \longrightarrow airflow obstruction \longrightarrow premature airway closure on expiration \longrightarrow dynamic hyperinflation \longrightarrow hypercarbia

❖ Dynamic hyperinflation or "air-trapping" also leads to ventilation/perfusion (V/Q) mismatching causing hypoxemia

Clinical presentations

- ❖ Cough
 - ❖ Wheezing
 - ❖ Increased work of breathing
 - ❖ Agitation
 - ❖ Altered level of consciousness
 - ❖ Inability to speak
 - ❖ Central cyanosis
 - ❖ Diaphoresis
 - ❖ Inability to lie down
- 

Clinical presentation

- ❖ **varies** by severity, asthmatic trigger, and patient age.
- ❖ **Degree of wheezing** does not correlate with severity of the disease.
- ❖ Presence of **pulsus paradoxus** correlates with the severity of asthma attack
- ❖ **HIGH RISK FACTORS FOR ASTHMA SEVERITY & FATALITY:**
 - Previous severe sudden deterioration
 - Past PICU admission
 - Previous respiratory failure with the need for mechanical ventilation

Assessment of severity

- ❖ Based on clinical observation of the child
- ❖ Severity of exacerbation is assessed by evaluating-
 - PR
 - RR , BP ,SPO2
 - use of accessory muscles ,
 - ability to complete a sentence
 - cyanosis
 - altered sensorium

Assessment of severity

Becker Asthma Score:

Score	Respiratory rate	Wheezing	I/E ratio	Accessory muscle use
0	<30	None	1:1.5	None
1	30-40	Terminal expiration	1:2	1 site
2	41-50	Entire expiration	1:3	2 sites
3	>50	Inspiration & entire expiration	>1:3	3 sites or neck strap muscle use

Score > 4 - Moderate asthma exacerbation

Score 7 or above - Severe & needs ICU admission

Assessment of severity

- ❖ Oxygen saturation should be closely monitored by pulse oximetry
- ❖ **Oxygen saturation** <90% signals the need for aggressive therapy
- ❖ **Complicating factors** such as pneumonia, atelectasis, pneumothorax, or pneumomediastinum should be identified early

Chest Radiography


Limited role but indicated in-

- ❖ First time wheezers
- ❖ Clinical evidence of parenchymal disease
- ❖ Those requiring admission to PICU
- ❖ Suspected air leak or pneumonia
- ❖ When the underlying cause of wheezing is in doubt


Arterial blood gas

- ❖ ABG should be done in all children at baseline and subsequently as indicated
- ❖ Usually **hypocarbica** in early stage
- ❖ **Normalisation of CO₂ with persistent respiratory distress** indicates impending respiratory failure
- ❖ A **PaO₂ <60** mmHg and a normal or increased **PaCO₂(>45** mmHg) indicates the presence of respiratory failure

Management

- ❖ PICU admission
 - ❖ IV access
 - ❖ Continuous pulse oximetry
 - ❖ Cardiorespiratory monitoring
 - ❖ Avoid sedation in non-intubated children
 - ❖ If ventilated- arterial and central venous access
- 


Fluids

- ❖ Restoration of euvolemia
 - ❖ Isotonic fluid like normal saline or ringer's lactate should be used for correction of dehydration
 - ❖ Once euvolemia is restored, maintenance IV fluids should be started
 - ❖ Avoid overhydration; Risk of pulm edema
 - ❖ Serum potassium monitoring
- 

Antibiotics

- ❖ Not routinely indicated
- ❖ Used in children with evidence of bacterial infection
 - High fever
 - Purulent secretion
 - Consolidation on X-ray film
 - Very high leukocyte counts

Oxygen

- ❖ Administered by nasal cannulae, by mask, or rarely by head box in some infants
 - ❖ Oxygen saturation monitoring with pulse oximetry
 - ❖ Maintain oxygen saturation 93-95%(94-98% for children 6-11yrs)
- 

Pharmacological therapies

- ❖ B2 agonist
- ❖ Steroids
- ❖ Anticholinergics
- ❖ Magnesium sulfate
- ❖ Aminophylline
- ❖ Ketamine
- ❖ Heliox

Child with acute asthma exacerbation

clinical assessment (pulmonary index score), pulse oximetry

CXR and ABG if indicated

Assessment of severity of status asthmaticus

Admit to PICU if Becker asthma score ≥ 7

Supportive care

Management

Pulmonary index score

1. Respiratory rate
2. Wheezing
3. Inspiration/expiration ratio
4. Accessory muscle use

- Comfortable environment
- IV access
- Maintain euvolemia
- Continuous cardio-respiratory monitoring
- Avoid sedation
- Monitor potassium
- Antibiotics, if indicated
- If ventilated, arterial and central venous access

Medications

Ventilation

medications

β_2 agonist

Anticholinergic

Corticosteroids

- **salbutamol continuous nebulization** 0.15–0.5 mg/kg/hr, or 10–20 mg/hr
- **Salbutamol intermittent nebulisation**–0.15 mg/kg at 20 min 3 times
- **salbutamol MDI with spacer** (100 mcg) 4–8 puffs
- **subcutaneous** Terbutaline – 0.01 mg/kg/dose (max 0.3 mg), may be repeated q 20–30 min for total 3 times
- **IV Terbutaline** – loading dose 10 mcg/kg IV over 10 min followed by 0.1–10 mcg/kg/min

- **Ipratropium bromide** 125 – 500 mcg (if nebulized)
- administered every 20 min for up to three doses
- Then every 4 – 6 hrs

- **Hydrocortisone ?**
- 10 mg/kg IV stat
- then 5 mg/kg IV q 6 hr
- switch to PO
- **Prednisolone** 1– 2 mg/kg/d when stable ,total 3 to 5 days
- **Methyl prednisolone–iv/im** 1–2mg/kg/day qd or bid for 3–7 days
- **Dexamethasone** –0.6 mg/kg/day orally OD for 1–2 days

Other medications

1. **Magnesium sulphate** - 25-75 (50) mg/kg/dose over 30 min or infusion at a rate of 10 - 20 mg/kg/hr , can repeat once or twice after 4-6 hrs

Nebulized isotonic magnesium sulphate -150 mg 3 doses in 1st hr of t/t in >2 yrs -benefit in some pts

2. **Theophylline** - loading dose of 5-7 mg/kg infused over 20 min followed by 0.5 - 0.9 mg/kg/hr

3. **Ketamine** - 1 mg/kg/hr , titrated to effect, usually combined with benzodiazepine infusion

4. **Vecuronium** - 0.1 mg/kg/hr , titrated to effect.

5. **fentanyl ,no morphine** for sedation as it releases

histamine

B2 agonist

- ❖ The mainstay of therapy
- ❖ Administered via inhalation, intravenous, subcutaneous, or oral routes
- ❖ Salbutamol & Terbutaline- preferred

No difference in clinical response to treatment with racemic salbutamol Vs levo- salbutamol in acute severe asthma in children

Qureshi F. et al. *Ann Emerg Med.* 2005;46:29-36.

Inhaled B2 agonist

- ❖ Continuous nebulisation
0.15-0.5 mg/kg/hr or 10-20 mg/hr
- ❖ Intermittent back-to-back nebulization
0.15 mg/kg
- ❖ MDI 4-10 puffs every 20 min

MDI with a holding chamber is at least as effective as nebulized salbutamol in young children with moderate to severe asthma exacerbations.

Castro-Rodriguez JA et al J Pediatr.2004;145:172-7

Intravenous B2 agonist

- ❖ Indications-

- Unresponsive to inhaled B2 agonist
 - Nebulization is not feasible(Intubated patients, Patients with poor air entry)

- ❖ Terbutaline is the intravenous agent of choice

- Loading dose of 10 mcg/kg IV over 10 min, followed by continuous infusion at 0.1-10 mcg/kg/min

No evidence to support the routine use of IV B2 agonist in acute severe asthma

Travers A. et al. *Cochrane Database Syst Rev*.2001;(2):
CD002988

Subcutaneous B2 agonist

- ❖ Primarily used for children with no IV access
- ❖ As a rapidly available adjunct to inhaled B2 agonist
- ❖ Subcutaneous Terbutaline
0.01 mg/kg/dose(max of 0.3 mg)
- ❖ May be repeated every 15-20 min for up to three doses


Anticholinergic agents

- ❖ Standard of care in the treatment of acute asthma in children in combination with B2 agonist
- ❖ Administered via inhaled route
- ❖ Most commonly used -Ipratropium bromide
- ❖ Ipratropium bromide-Nebulisation/MDI
125-500 mcg or 4-8 puffs every 20 min for up to three doses
- ❖ Subsequently every 4-6 hr

Corticosteroids

- ❖ First line of therapy
- ❖ Oral or parenteral corticosteroids have equal efficacy
- ❖ Parenteral steroids - preferred for critically ill children
- ❖ Whenever possible, administered within 1 hr of presentation
- ❖ Aerosolized corticosteroids-limited role
- ❖ Commonly used parenteral steroids
 - Hydrocortisone
 - Methyl prednisolone
 - Dexamethasone

Magnesium sulphate

- ❖ Studies showed some benefit of adding IV magnesium sulfate to nebulized B agonists and corticosteroids
 - ❖ Dose-50 mg/kg/dose over 30 min or by continuous infusion at a rate of 10-20 mg/kg/hr
 - ❖ May be repeated once or twice after 4-6hrs
- 

Aminophylline

- ❖ Loading dose: 5-7 mg/kg over 20 min
- ❖ Continuous infusion: 0.5-0.9 mg/kg/hr

- ❖ Limited role in children unresponsive to steroids, inhaled and IV B2 agonist, and O2.
Ream RS et al. Chest 2001;119:1480-8.

Mechanical Ventilation

Indications-

- ❖ Poor response to initial therapy
- ❖ Severe hypoxia
- ❖ Rapid deterioration in mental state
- ❖ Rising PCO_2
- ❖ Cardiopulmonary arrest

Ventilation



Non - invasive ventilation



Non - invasive positive pressure ventilation should be tried prior to conventional ventilation




Invasive ventilation




- Volume control mode
- $V_T < 6$ ml/kg
- RR approximately half of the normal for age
- I:E ratio 1:3
- PEEP of 0-2 cm of H_2O
- In Infants - pressure control ventilation with PIP adjusted

Intubation Tips

- ❖ Preoxygenate with 100% oxygen
 - ❖ Cuffed ET tube with the largest appropriate diameter should be used
 - ❖ Avoid histamine producing agents like morphine or atracurium
 - ❖ Ketamine-preferred induction agent due to its bronchodilatory action
 - ❖ Use atropine ,Benzodiazepam and a rapid acting muscle relaxant(Vecuronium)
- 

Ventilation Strategy

- ❖ Maintain adequate oxygenation
 - ❖ Permissive hypercarbia and adjust minute ventilation to maintain arterial pH of >7.2
 - ❖ Slow ventilator rates
 - ❖ Prolonged expiratory phase
 - ❖ Short inspiratory time
 - ❖ Minimal PEEP(controversial)
- 

Ventilator setting

- ❖ Vt of 5-6 ml/kg
- ❖ RR approximately half of the normal for age
- ❖ I:E ratio of 1:3
- ❖ PEEP of 0-2 cm of H₂O
- ❖ In infants, pressure controlled ventilation may be used with PIP adjusted to achieve adequate ventilation

Sedation, Analgesia and Muscle Relaxants

- ❖ Sedation is generally not indicated except
 - Excessively anxious children(not hypoxemic or hypercarbic)
 - Intubated children
- ❖ Mechanically ventilated children require heavy sedation
- ❖ Ketamine(1-2 mg/kg/hr) is a good choice
- ❖ Among opiates, fentanyl is preferred
- ❖ Vecuronium is commonly used to achieve paralysis

Heliox

- ❖ Reasonable adjunct therapy
- ❖ Indications-
 - Children unresponsive to conventional therapy
 - Children on high pressure mechanical ventilatory support

Colebourn CL et al. Anaesthesia 2007;62:34-42

Noninvasive Mechanical Ventilation

- ❖ An alternative to conventional mechanical ventilation in early phase
- ❖ While weaning off from conventional ventilator

Carroll CL, Schramm CM, Ann Allergy Asthma Immunol.2006;96:454-9

Leukotriene Modifiers

- ❖ Little data to suggest a role for leukotriene modifiers in acute asthma
- ❖ It is not part of standard management of status asthmaticus

Todi VK, Lodha R, Kabra SK. Arch Dis Child. 2010;95:540-3

Chest Physiotherapy

- ❖ Useful in children with segmental or lobar atelectasis
- ❖ In others no therapeutic benefit in the critically ill patient with status asthmaticus



.com

T

H A

N K

Y

O

U

U

WALK TO CURIADETES
2005

WALK TO CURIADETES
2005

WALK TO CURIADETES
2005

WALK TO CURIADETES
2005

WALK TO CURIADETES
2005

WALK TO CURIADETES
2005

WALK TO CURIADETES
2005

WALK TO CURIADETES
2005